Necrostatin-1 is a specific RIP1 inhibitor and inhibits TNF-α-induced necroptosis with EC50 of 490 nM in 293T cells.
A powerful tool for characterizing the role of necroptosis with characterized primary target.
Necrostatin-1 (1-100 μM) inhibits the autophosphorylation of overexpressed and endogenous RIP1.It is found RIP1 is the primary cellular target responsible for the antinecroptosis activity of Necrostatin-1. Necrostatin-1 efficiently suppresses necroptotic cell death triggered by an array of stimuli in a variety of cell types. Necrostatin-1, previously identified as small-molecule inhibitor of necroptosis, inhibits RIP kinase-induced necroptosis and inhibits TNF-α-induced necroptosis in jurkat cells with EC50 of 490 nM.
Necrostatin-1 (4311-88-0) is an inhibitor of necroptosis (non-apoptotic cell death pathway; EC50 = 494 nM).1 It is an ATP-competitive death domain receptor-associated adaptor kinase (RIP1) inhibitor (EC50 = 182 nM).2 Necrostatin-1 displays a protective effect in a mouse model of ischemic brain injury1, inhibits myocardial cell death and reduces infarct size in various mouse heart models3 and inhibits glutamate-induced oxytosis in HT-22 cells4.
Necroptosis is a regulated caspase-independent cell death mechanism that results in morphological features resembling necrosis. Necrostatin-1 is an inhibitor of RIP1 kinase that prevents the death of TNF-α-treated FADD-deficient Jurkat cells. Necrostatin-1 has been used to investigate the pathological importance of necroptosis in ischemic brain injury and myocardial infarction.
Necroptosis is a regulated caspase-independent cell death mechanism that results in morphological features resembling necrosis. Necrostatin-1 is an inhibitor of RIP1 kinase that prevents the death of
TNF-α-treated FADD-deficient Jurkat cells. Necrostatin-1 has been used to investigate the pathological importance of necroptosis in ischemic brain injury and myocardial infarction.
Necrostatin-1 is a specific RIP1 inhibitor and inhibits TNF-α-induced necroptosis with EC50 of 490 nM.
ChEBI: 5-(1H-indol-3-ylmethyl)-3-methyl-2-sulfanylidene-4-imidazolidinone is an organonitrogen compound and an organooxygen compound. It is functionally related to an alpha-amino acid.
ATP-competitive death domain receptor-associated adaptor kinase (RIP1) allosteric inhibitor (EC 50 = 182 nM). Blocks non-apoptotic cell death via inhibition of a specific cellular pathway, necroptosis, which leads to necrosis (EC 50 = 494 nM). Reduces ischemic brain injury in a mouse model of stroke.
Necrostatin-1(Nec-1) might exhibit therapeutic benefit against patients with traumatic brain injury (TBI). In addition, it might also be used to treat other acute central nervous system (CNS) disorders that feature necroptosis as a mode of cell death. It is extensively used to study the effect of receptor-interacting protein kinase 1 (RIPK1) on cell death and inflammation in experimental disease models. Nec‐1 protects hippocampal (HT‐22) cells from glutamate‐induced oxytosis via increasing cellular glutathione (GSH) levels, decreasing reactive oxygen species production, inhibiting the nuclear translocation of apoptosis‐inducing factor and B-cell lymphoma 2 (Bcl‐2) /adenovirus E1B 19kDa‐interacting protein 3‐related pathways.
previous study indicated that necrostatin-1 was a selective allosteric inhibitor of the death domain receptor–associated adaptor kinase rip1 in vitro. in this study, rip1 was found to be the primary cellular target responsible for the antinecroptosis activity of necrostatin-1. in addition, two other necrostatins, necrostatin-3 and necrostatin-5, were also shown to target the rip1 kinase step in the necroptosis pathway, but through different mechanism compared with that of necrostatin-1. the findings established necrostatins as the first-in-class inhibitors of rip1 kinase, the key upstream kinase involved in the activation of necroptosis [2].
a previous study was designed to investigate the protective effects and mechanisms of nec-1 in concanavalin a-induced hepatitis in mice. it was found that in nec-1-treated mice the amelioration in liver functions and histopathological changes and the suppression of inflammatory cytokine production were observed. western blotting analyses showed that the expression of tnf-α, ifn-γ, il2, il6, and rip1 was significantly reduced in the nec-1-treated mice, which was further confirmed by immunofluorescence and immunohistochemistry. in addition, autophagosome formation was significantly reduced by nec-1 treatment. these results indicated that nec-1 could prevent concanavalin a -induced liver injury via rip1-related and autophagy-related pathways [3].
necrostatin-1 (nec-1), (r)-5-([7-chloro-1h-indol-3-yl]methyl)-3-methylimidazolidine-2,4-dione (nec-1a) (figure 1a) (degterev et al., 2008), exhibited an inhibitory constant (ic50) of 0.32 mm for rip1 [1].
1) Degterev, et al. (2005), Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury‘ Nature Chem. Biol., 1 112
2) Degterev et al. (2008) Identification of RIP1 kinase as a specific cellular target of necrostatins; Nature Chem. Biol., 4 313
3) Smith et.al. (2007), Necrostatin: a potentially novel cardioprotective agent?; Cardiovasc. Drugs Ther., 21 227
4) Xu et.al. (2007), Necrostatin-1 protects against glutamate-induced glutathione depletion and caspase-independent cell death in HT-22 cells; J. Neurochem., 103 2004
